On 5/8/24, Pacira BioSciences Inc (NASDAQ: PCRX) stock enjoyed a major increase of 11.8%, closing at $29.65. Moreover, exceptionally high trading volume at 386% of normal accompanied the advance. The stock has risen 13.0% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, PCRX is expected to continue to be an important Value Builder.
Pacira BioSciences has a current Value Trend Rating of D (Negative). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Pacira BioSciences has a slightly positive Appreciation Score of 64 but a very low Power Rating of 13, and the Negative Value Trend Rating results.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment